Sigma Metric Analysis
Continuing in our series of CLIA 2025 check-ups, we take a look at an example cobas e801 in the US. Can these IA assays hit the new goals?
Continuing in our series of CLIA 2025 check-ups, we take a look at an example Vitros XT 7600 in the US. Is IA on the dry side better suited for the new goals?
Continuing in our series of CLIA 2025 check-ups, we take a look at an example Alinity in the US. IA assays have harder goals to hit come January 1st. Will the new year bring joy, or sorrow?
Continuing in our series of CLIA 2025 check-ups, we take a look at an example Atellica in the US. Can it pass the new goals for CLIA? Or is January 1st going to be the start of an agonizing year?
After GAMECHANGE, we were flooded with requests by laboratories who worried that they were going to fail the new CLIA 2025 PT rules. Volunteered data allowed us to provide some benchmarking and understand who was in trouble and who wasn't. An anonymous example shows what methods are safe and what are in jeopardy.